BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in ...

Objectives This study proposes the evaluation of receptors associated with retrotranscytosis CD71 and Dectin-1 (Dec-1) in gut tissues from SpA without IBD patients to explore a possible mechanism ...

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022. (HealthDay News) — Among U.S. adults without diabetes, the use of glucagon-like ...

The annual prevalence increased to 0.4% by 2022, with an estimated 854,728 adults without diabetes using GLP-1 RAs. HealthDay News — Among US adults without diabetes, the use of glucagon-like ...

The result is "consistent with prior studies of injectable semaglutide and other GLP-1 receptor agonist," but a positive result is still a big deal, said principal investigator Darren K.

The researchers found that while most glucose-lowering therapies were not significantly associated with a reduction in dementia risk, one class of drugs—known as GLP-1 receptor agonists (GLP ...

Doctors believe that GLP-1 agonists work by binding to receptors that tell your body to release the hormone GLP-1, which is responsible for regulating your hunger and triggers the release of insulin.

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...